Chicago, July 14 (Reuters) – All 45 healthy volunteers developed an immune response to An experimental novel coronavirus vaccine that showed it was safe in an early study under way, U.S. researchers said on Wednesday.
And these vaccines are about to begin crucial final testing.
The team reports in the US weekly New England Journal of Medicine that the volunteers who received both doses of the vaccine produced high levels of antibodies to the virus, higher than the average level in recovered coVID-19 patients.
None of the volunteers reported serious side effects, but more than half reported mild or moderate reactions, such as fatigue, headaches, chills, muscle pain or pain at the injection site, the report said.
These reactions were more likely to occur in volunteers who received the second dose of the vaccine and the highest dose.
The experimental vaccine, developed by the National Institutes of Health and Merck, will enter its most important phase around July 27:30,000 people will participate in a study to see if it is really effective enough to prevent COVID-19.